Article Information
History
- October 13, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Mohammadali Alidoost1,
- Jeremy Y. Huang2,
- Georgia Dermentzaki3,
- Anna S. Blazier3,
- Giorgio Gaglia2,
- Timothy R. Hammond3,
- Francesca Frau4,
- Mary Clare Mccorry5,
- Dimitry Ofengeim3 and
- Jennifer L. Wilson1,*
- 1Department of Bioengineering, University of California Los Angeles, Los Angeles, CA, 90095, USA
- 2Precision Medicine & Computational Biology, Sanofi Research US, Cambridge, MA, 01701, USA
- 3Rare & Neurologic Diseases, Sanofi Research US, Cambridge, MA, 01701, USA
- 4Evidence Generation & Decision Sciences, Sanofi Development, Frankfurt, 65929, Germany
- 5Scientific Relations & Initiatives, Sanofi Research US, Cambridge, MA, 01701, USA
- ↵*To whom correspondence should be addressed: Jennifer L Wilson, jenniferwilson{at}g.ucla.edu, 420 Westwood Plaza, 5121 Eng V, Rm 4121D, Los Angeles CA, 90095, USA
Posted October 13, 2024.
Learning good therapeutic targets in ALS, neurodegeneration, using observational studies
